Antihyperglycaemic and organic protective effects on pancreas, liver and kidney by polysaccharides from *Hericium erinaceus* SG-02 in streptozotocin-induced diabetic mice

Chen Zhang, Juan Li, Chunlong Hu, Jing Wang, Jianjun Zhang, Zhenzhen Ren, Xinling Song & Le Jia

The present work was designed to investigate the antihyperglycaemic and protective effects of two *Hericium erinaceus* intracellular polysaccharide (HIPS) purified fractions (HIPS1 and HIPS2) from mycelia of *H. erinaceus* SG-02 on pancreas, liver and kidney in streptozotocin (STZ)-induced diabetic mice. The supplementation of HIPS1 and HIPS2 significantly decreased the blood glucose (GLU) levels; suppressed the abnormal elevations of alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea nitrogen (BUN) and creatinine (CRE) levels in serum; improved the antioxidant enzymatic (superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and catalase (CAT)) activities; and attenuated the pathological damage to these organs. The HIPS1 showed superior effects in antihyperglycaemia and organic protection than HIPS2 possible owing to the abundant functional groups (-NH₂, -COOH and S=O) in HIPS1, indicating that *H. erinaceus* SG-02 could be used as a functional food and natural drug for the prevention of diabetes and its complications.

Diabetes mellitus (DM), the most significant chronic disease, which is characterized by hyperglycaemia and is associated with disturbances in carbohydrate, protein and fat metabolism, has become a global public health issue due to its prevalence and high morbidity. Clinically, DM can be classified into two types: type I (insulin-dependent DM) and type II (non-insulin-dependent DM). The former (type I) is always accompanied with complications such as vision loss, renal failure and nerve damage, while the latter (type II) is characterized by peripheral insulin resistance and impaired insulin secretion, leading to cardiovascular system diseases. Many factors have potential effects that raise the risk of DM, including viral infections, autoimmune diseases, unnatural diets, environmental factors, and other variables. Recently, increasing literature reports of both clinical and experimental studies have demonstrated that oxidative stress plays a vital role in the progression of DM and its complications. Streptozotocin (STZ), depending on its biotoxicity on pancreatic β-cells, which play important roles in the homeostasis of blood glucose through insulin synthesis, has been commonly used as an agent for experimentally inducing DM. The cellular mechanisms of β-cell destruction may be correlated with local reactive oxygen species (ROS) and nitric oxide (NO), which are induced by cytokine stimulation. In addition, the liver and kidneys, the detoxifying organs of the body, are affected by STZ-induced oxidative stress, which causes structural damage. Antioxidant agents can increase the expression of antioxidant enzymes and alleviate oxidative stress in both serum and organs, which can enhance the resistance to DM. Therefore, the antihyperglycaemic effects of some antioxidants should be investigated.

1. College of Life Science, Shandong Agricultural University, Taian, 271018, China. 2 Chinese Academy of Agricultural Sciences, Beijing, 100081, China. 3 College of Forestry, Shandong Agricultural University, Taian, 271018, China. 4 The Central Hospital of Taian, Taian, 271000, China. Chen Zhang, Juan Li and Chunlong Hu contributed equally to this work. Correspondence and requests for materials should be addressed to L.J. (email: jiale0525@163.com)
Clinically, insulin injection and oral administration of hypoglycaemic agents are two traditional therapies for treating DM. Among such treatments, the control of postprandial hyperglycaemia is critical in early therapy for DM. One therapeutic approach to decrease postprandial hyperglycaemia is to retard the absorption of glucose by inhibiting carbohydrate-hydrolysing enzymes, such as α-amylase and α-glucosidase, in digestive organs. The inhibition rate for carbohydrate-hydrolysing enzymes could be regarded as a preliminary indicator for the effectiveness of therapeutic agents. Recently, common oral hypoglycaemic agents, such as sulfonylureas and biguanides, have been blamed for their side effects during long-time use and yield little therapeutic efficacy against diabetic complications. Hence, alternative medicines and natural therapies with non-toxic properties have gained further academic attention. As an alternative approach, mushrooms have been widely used in medical applications due to the abundant bioactive compounds they contain, which have potential anticarcinogenic, anti-inflammatory, hypolipidaemic, antidiabetic and hepatinica activities. Interestingly, it has previously been demonstrated that polysaccharides from mushrooms, such as Pleurotus djamor, Phellinus baumii and Agrocybe cylindracea, have significant effects in the treatment of DM and its complications.

Hericium erinaceus (H. erinaceus), an edible fungus that inhabits mountainous areas, has been used in traditional folk medicine and medicinal cuisine in the northeast territories of Asia. Previous pharmacological studies have confirmed that H. erinaceus has potential medicinal applications in the treatment and prevention of hyperglycaemia, chronic bronchitis, cancer, arteriosclerosis, hypertension, hypercholesterolemia and leucopenia. In recent years, basic studies on the chemical identification of the active ingredients of H. erinaceus have progressed, and polysaccharides have been identified as the main effective components. Submerged cultures have become a main source of polysaccharides, having the advantage of shorter incubation times and higher production levels compared with common cultures. To the best of our knowledge, up to this point, there have been no reports regarding any protective effects of mycelia polysaccharides from H. erinaceus SG-02 on pancreas, livers and kidneys in STZ-induced diabetic mice.

In this article, two new intracellular polysaccharides were successfully isolated from mycelia of H. erinaceus SG-02. Their antihyperglycaemic and inhibitory effects on carbohydrate-hydrolysing enzymes and their protective effects on pancreas, livers and kidneys in STZ-induced diabetic mice were investigated. Moreover, their monosaccharide compositions and infrared spectra were also analysed.

Results

Purification of H. erinaceus intracellular polysaccharide (HIPS). As shown in Fig. 1, two elution peaks, HIPS1 and HIPS2, were purified via DEAE-52 anion-exchange chromatography. HIPS1 was a neutral polysaccharide, as it was eluted with distilled water, while HIPS2 was an acidic polysaccharide, as it was eluted with a 0.3 mol/L NaCl solution. Individual peaks of both HIPS1 and HIPS2 were purified using a Sephadex G-100 cellulose column (Fig. 1B and C), demonstrating that the two fractions were both homogeneous and pure. The yields of HIPS1 and HIPS2 were 21.62 ± 0.74% and 32.75 ± 1.21%, respectively.
Ultraviolet (UV) spectroscopy, Gas chromatography (GC) and Fourier transform infrared (FT-IR) analysis of polysaccharides. The UV scanning spectrums of HIPS1 and HIPS2 showed no absorption at 280 and 260 nm, indicating the polysaccharides were purified and free of nucleic acids and proteins.

The monosaccharide compositions of HIPS1 and HIPS2 are shown in Fig. 2. HIPS1 was composed of xylose (Xyl) (3.02%), mannose (Man) (4.36%), galactose (Gal) (9.41%) and glucose (Glc) (83.21%), with molar ratios of 1:1.2:2.6:23.1 (Fig. 2B), while HIPS2 contained Man, Gal and Glc, with mass percentages of 23.40%, 50.34% and 26.27%, and molar ratios of 1:2.15:1.12 (Fig. 2C), respectively.
FT-IR spectra of HIPS1 and HIPS2 are shown in Fig. 2. It is obvious that both HIPS1 and HIPS2 exhibited typical major -OH broad stretching bands for carbohydrates at approximately 3500–3400 cm\(^{-1}\). The absorption peaks at 1637.85 and 1637.37 cm\(^{-1}\) are attributed to the stretching vibration of C=O. The bands at approximately 1618 cm\(^{-1}\) indicate the presence of -NH\(_2\) in the two samples. The absorption peak for HIPS1 at 2030.49 cm\(^{-1}\) is a characteristic absorption peak for C≡C\(^{26}\), and the bands at approximately 1450 cm\(^{-1}\) indicate the presence of -COOH groups in HIPS1\(^{27}\). The band at approximately 1153 cm\(^{-1}\) suggests valent vibrations of the C-O-C bond and a glycosidic bridge in HIPS1\(^{23}\), while \(\alpha\)-glucan\(^{28}\) had an additional band at 1026 cm\(^{-1}\). The characteristic absorption peak at 866.03 cm\(^{-1}\) indicates the presence of a furan ring in HIPS1\(^{13}\), while the additional weak peak at approximately 620.83 cm\(^{-1}\) describes S=O vibrations in HIPS1\(^{26,29}\).

**Inhibitory effects on \(\alpha\)-amylase and \(\alpha\)-glucosidase activities.** The inhibitory effects of HIPS1 and HIPS2 on \(\alpha\)-amylase and \(\alpha\)-glucosidase activities were investigated in the present work. As shown in Fig. 3, the inhibitory activities of HIPS2 on \(\alpha\)-amylase and \(\alpha\)-glucosidase were lower than those of HIPS1. The \(\alpha\)-amylase inhibition rate of HIPS1 (53.27 ± 2.16%) was maximal at a concentration of 5 mg/mL, which was 32.09% higher than that for HIPS2. The 50% inhibitory concentration (IC\(_{50}\)) value for HIPS1 on \(\alpha\)-amylase activity was 3.42 ± 0.29 mg/mL, and the inhibition rate declined at concentrations greater than 5 mg/mL. At a concentration of 6 mg/mL, the \(\alpha\)-glucosidase inhibition rate of HIPS1 was 36.64 ± 1.83%, which was 14.21% higher than that for HIPS2.

**Effects of HIPS1 and HIPS2 on blood glucose (GLU) levels, body weights, and pancreas, liver and kidney indices.** The results for GLU levels, body weight, and pancreas, liver and kidney indices in STZ-induced diabetic mice are listed in Table 1. Before treatment, the GLU levels of the diabetic mice were markedly increased than those of normal mice (Table 1, \(P < 0.05\)). After treatment, the GLU levels in the six dose groups were significant decreased than that in the MC groups, indicating that the pathological increases could be suppressed by HIPS1 and HIPS2 administration at different doses (\(P < 0.05\)). Specifically, compared with the MC group, the final GLU levels in the H-HIPS1, M-HIPS1, L-HIPS1, H-HIPS2, M-HIPS2 and L-HIPS2 groups were reduced by 51.65 ± 9.11, 38.77 ± 5.48, 34.21 ± 6.54, 37.05 ± 6.80, 32.56 ± 9.67 and 28.93 ± 5.94%, respectively. Additionally, both HIPS1 and HIPS2 showed effects in reducing GLU levels but the values remained different in comparison with that in NC groups among the test doses.

The body weights of pre-treatment and post-treatment diabetic mice were also determined. At the onset of the experiments, there was no significant difference (\(P < 0.05\)) between the body weights of normal and diabetic mice, while the diabetic mice without any treatment had emaciated bodies compared with the seven treatment
groups at the end of the study. Specifically, the body weights of mice in the NC groups were significantly \((P < 0.05)\) increased during the treatment. However, the diabetic mice in the MC group exhibited significant weight loss \((P < 0.05)\). When compared with that in the MC groups, the mice in H-HIPS1, M-HIPS1, L-HIPS1, H-HIPS2 and M-HIPS2 groups showed significant improvements on the body weights \((P < 0.05)\). And the results also indicated that HIPS1 showed stronger effects in improving the body weights, which was reflected by the paralleled values in comparison with that in the NC groups.

Furthermore, the indices for the pancreas, liver and kidneys in the mice were also investigated, and the results are listed in Table 1. Significant increases in the pancreas, liver and kidney indices were observed in the diabetic mice (MC) group compared with those in the NC group \((P < 0.05)\). However, the three indices were decreased after treatment with HIPS1 and a high dose of HIPS2. Especially in the H-HIPS1 group, the pancreas, liver and kidney indices of the mice were reduced by 32.01 ± 2.16, 22.71 ± 2.94 and 39.11 ± 3.32%, respectively, compared with those in the MC group. However, HIPS2 was much less effective than HIPS1 in restoring the organ indexes, especially at the low dose.

**Effects of HIPS1 and HIPS2 on serum biochemistry.** The activities and levels of albumin (ALB), alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea nitrogen (BUN) and creatinine (CRE) in serum are clinically used as biochemical markers for early liver and kidney damage. As shown in Table 2, mice exhibited liver and kidney damage after injection with STZ, as evidenced by significant increases in the serum levels of ALP, ALT, AST, BUN and CRE \((P < 0.05)\) and decreased ALB levels. Dramatically, when compared with that in the MC groups, the activities of ALT, AST and ALP as well as the levels of BUN and CRE were significantly \((P < 0.05)\) decreased, while the ALB levels were increased by treatment with HIPS1 at the three tested dosages. However, only the high dose of HIPS2 (600 mg/kg) was effective in maintaining the above effectiveness. Particularly, the serum biochemical parameters for mice in the H-HIPS1 groups were similar to that in normal mice, indicating the high dose of HIPS1 was much more effective than the other doses of HIPS1 and HIPS2. In the present work, HIPS1 could suppress the abnormal elevations of ALP, ALT, AST, BUN and CRE levels and the decline in ALB levels in diabetic mice, indicating that the polysaccharides extracted from *H. erinaceus* SG-02 had potential protective effects against STZ-induced liver and kidney damage. Additionally, supplementation with glibenclamide could achieve effects similar to supplementation with HIPS1 (Table 2).

**Effects of HIPS1 and HIPS2 on GSH peroxide (GSH-Px), superoxide dismutase (SOD), catalase (CAT), and malondialdehyde (MDA).** To study the effects of HIPS1 and HIPS2 administration on enzymatic activities and free radical production, GSH-Px, SOD and CAT activities and MDA levels were measured.

### Table 1. Effects of HIPS1 and HIPS2 on the GLU levels, body weights, as well as index of pancreas, liver and kidney. The values are reported as the means ± SD \((n = 10\) for each group). Means with the same letter are not significantly different \((P < 0.05)\). *Significant difference compared to Pre-treatment \((P < 0.05)\).

| Group | GLU levels (mmol/L) | Body weight (g) | Pancreas index (g/100 g) | Liver index (g/100 g) | Kidney index (g/100 g) |
|-------|---------------------|-----------------|--------------------------|-----------------------|-------------------------|
|       | Pre-treatment       | Post-treatment  | Pre-treatment            | Post-treatment        |                         |
| NC    | 4.13 ± 0.21a        | 4.18 ± 0.12a    | 25.23 ± 1.21a            | 34.29 ± 1.12a*        | 1.76 ± 0.13a            |
| MC    | 13.82 ± 0.15c       | 15.14 ± 0.56b*  | 24.16 ± 0.95a            | 25.24 ± 0.97d         | 2.78 ± 0.27d            |
| PC    | 14.76 ± 0.17b       | 5.35 ± 0.41a    | 23.93 ± 0.32a            | 32.77 ± 1.13ab*       | 2.31 ± 0.25c            |
| H-HIPS1 | 14.05 ± 0.58c     | 7.32 ± 0.82c*   | 24.89 ± 0.68a            | 31.38 ± 1.42ab*       | 1.89 ± 0.21ab           |
| M-HIPS1 | 13.67 ± 0.32c      | 9.27 ± 1.17d*   | 25.83 ± 0.86a            | 30.19 ± 1.17abc*      | 1.92 ± 0.16ab           |
| L-HIPS1 | 13.87 ± 0.13c      | 9.96 ± 0.45cd*  | 24.97 ± 0.79a            | 28.96 ± 0.59bc*       | 2.23 ± 0.11bc           |
| H-HIPS2 | 13.98 ± 0.49c      | 9.53 ± 0.47d*   | 25.44 ± 0.47a            | 29.05 ± 1.51bc*       | 2.21 ± 0.23bc           |
| M-HIPS2 | 14.87 ± 0.25b      | 10.21 ± 0.91cd* | 25.47 ± 1.18a            | 29.21 ± 0.92c*        | 2.26 ± 0.22bc           |
| L-HIPS2 | 13.99 ± 0.31c      | 10.76 ± 0.34e*  | 25.03 ± 1.31a            | 27.56 ± 1.21b*        | 2.58 ± 0.15cd           |

### Table 2. Effects of HIPS1 and HIPS2 on serum biochemistry in different groups. The values are reported as the means ± SD \((n = 10\) for each group). Means with the same letter are not significantly different \((P < 0.05)\).

| Group | ALB (g/L) | ALP (U/L) | ALT (U/L) | AST (U/L) | BUN (mmol/L) | CRE (µmol/L) |
|-------|-----------|-----------|-----------|-----------|--------------|--------------|
|       | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment |              |              |
| NC    | 35.65 ± 2.47a | 121.67 ± 13.66a | 37.41 ± 3.56a | 116.42 ± 13.36a | 6.23 ± 1.9a | 60.27 ± 2.19a |
| MC    | 12.74 ± 3.78f | 183.13 ± 20.14d | 126.38 ± 15.37e | 217.83 ± 30.55f | 8.17 ± 0.21d | 93.53 ± 10.38d |
| PC    | 30.79 ± 3.80bc | 138.21 ± 9.76ab | 47.93 ± 7.31ab | 142.29 ± 17.45bc | 6.57 ± 0.44ab | 66.22 ± 2.95ab |
| H-HIPS1 | 31.21 ± 3.52b | 139.52 ± 10.59b | 44.98 ± 5.99a | 155.27 ± 16.11ab | 6.81 ± 0.33ab | 66.32 ± 4.31ab |
| M-HIPS1 | 29.28 ± 4.33c | 150.67 ± 8.33bc | 62.13 ± 10.96b | 151.12 ± 16.51bc | 7.21 ± 0.11bc | 75.22 ± 3.34bc |
| L-HIPS1 | 23.78 ± 5.62de | 159.53 ± 13.55bc | 88.74 ± 16.51c | 188.67 ± 9.64d | 7.86 ± 0.31cd | 78.66 ± 4.92c |
| H-HIPS2 | 25.95 ± 1.49cd | 161.07 ± 15.33bcd | 83.77 ± 16.59c | 180.29 ± 15.49d | 7.95 ± 0.12cd | 75.49 ± 7.47c |
| M-HIPS2 | 20.87 ± 3.38e | 168.42 ± 11.57cd | 109.21 ± 18.65d | 186.44 ± 13.87e | 8.09 ± 0.28cd | 86.08 ± 6.85cd |
| L-HIPS2 | 17.99 ± 3.05e | 172.69 ± 15.94cd | 115.39 ± 20.19de | 194.41 ± 22.51e | 8.26 ± 0.39cd | 87.24 ± 3.77d |
in the three organs (Fig. 4). At the end of the experiment, the GSH-Px, SOD, CAT and MDA activities in STZ-induced diabetic mice (MC groups) were significantly reduced \( (P < 0.05) \), while MDA levels were markedly increased \( (P < 0.05) \) compared with those in the NC groups, indicating that the pancreas, liver and kidney all suffered oxidative stress. As shown in Fig. 4, the abnormal physiological and biochemical changes in the three organs of diabetic mice were restored by HIPS1 and HIPS2 administration. The GSH-Px, SOD and CAT activities in the liver reached maximum values of 72.75 ± 4.38, 158.68 ± 16.42 and 223.14 ± 26.12 U/mg protein, respectively, in the H-HIPS1 group, values that were significantly higher than those in the MC group (20.98 ± 3.26, 65.85 ± 5.31 and 74.96 ± 9.41 U/mg protein), respectively, \( (P < 0.05 \) for all), and with no significant difference compared to the NC group (Fig. 4A–C). The hepatic MDA levels reached 5.98 ± 0.23 μmol/L in the H-HIPS1 group, which was reduced by 49.14 ± 6.72% compared with those in the MC groups (Fig. 4D).

Similar results were also observed for GSH-Px, SOD and CAT activities in the kidney (Fig. 4E–G) and pancreas (Fig. 4I–L). When compared with the MC group, significant \( (P < 0.05) \) increases were observed after the administration of HIPS1 (including the three doses) and HIPS2 (including the high dose and middle dose). The MDA levels for the kidney (Fig. 4H) and pancreas (Fig. 4L) also declined after treatment with the polysaccharides.

Figure 4. Effects of HIPS1 and HIPS2 on GSH-Px, SOD, CAT, and MDA in liver (A–D), kidney (E–H) and pancreas (I–L). The values are reported as the means ± SD \( (n = 10 \) for each group). Means with the same letter are not significantly different \( (P < 0.05) \).
Glibenclamide-treated mice also manifested significant increases in SOD, GSH-Px, and CAT activities, and decreases in the MDA levels in the three organs compared with diabetic mice ($P < 0.05$).

The relevant indices in the H-HIPS1 group were approximately equal to those in the NC group. This conclusion demonstrated that the high dose of HIPS1 exhibited strong potential antioxidant effects against oxidative stress in the liver, kidney and pancreas.

**Histopathological observations of the pancreas, liver and kidney.**  
Histopathological observations of the pancreas, liver and kidney were performed using haematoxylin and eosin (HE) staining (Figs 5–7).

The effects of HIPS1 and HIPS2 on pancreatic tissues are shown in Fig. 5. Severe degeneration in the pancreas appeared in the STZ-induced diabetic mice, including lymphocyte infiltration, hypochromatosis and the disappearance of cell borders in the pancreatic islets (Fig. 5B). After treatment with HIPS1 at all doses and HIPS2 at the high and middle doses, improvement in the pancreatic tissues could be observed, which could be evidenced by decreased infiltration and more integrated cell structure in the pancreatic islets compared with the mice in the MC group (Fig. 5D–I). These results indicated that treatment with polysaccharides from *H. erinaceus* SG-02 could repair islet damage and improve the structural integrity of pancreatic islet beta-cells and tissues.

As shown in Fig. 6A, the hepatocyte morphology was normal, and the hepatic cells were arranged in a regular manner with abundant cytoplasm, distinct cell borders and normal central nuclei. In the MC group, liver damage was observed in the mice treated with STZ. The changes in hepatocyte morphology were characterized by perivascular inflammatory cell infiltration, fatty degeneration, hypochromatosis and the disappearance of cell borders (Fig. 6B). In the dosage groups, treatment with HIPS1 (600 and 400 mg/kg) and HIPS2 (600 mg/kg)
showed effects in ameliorating the liver damage (Fig. 6D,E and G). Especially for mice in the H-HIPS1 groups, the liver structures were similar to normal liver architectures (Fig. 6D).

The changes in kidney cortex histology are shown in Fig. 67. Compared with the mice in the NC groups with normal architecture (Fig. 7A), glomerular augmentation, glomerular swelling, mesangial matrix proliferation and loss of interstitial space were observed in mice in the MC group after STZ injection (Fig. 7B), indicating that kidney damage occurred in the diabetic mice. After the treatments with HIPS1 at high and middle doses, these pathological changes were attenuated, which were evidenced by the normal morphology of glomerulus in Fig. 7D and C.

Interestingly, the histopathological analysis of the pancreas and liver was consistent with the results of enzyme activities and MDA levels as biochemical indicators of their function (Table 2 and Fig. 4). Histological studies of the kidney cortices of mice in the H-HIPS1 and PC groups demonstrated similarities to those in the NC group, which echoed the results of the biochemical assays (Table 2 and Fig. 4).

**Acute toxicity.** In the acute toxicity assays, the mice treated with HIPS1 and HIPS2 did not exhibit any gross behavioural changes (including irritation, restlessness, respiratory distress, abnormal locomotion and catalepsy) or toxic symptoms (such as decreased food intake or shaggy hair) either immediately or during the post-treatment period compared with the control group, indicating that these polysaccharides were essentially non-toxic substances.

**Discussion**

Increasing data indicate enhanced oxidative stress and changes in antioxidant capacity in both clinical and experimental forms of DM that are key mechanisms in the pathogenesis of diabetic complications. STZ injection has been used to establish an experimental hyperglycaemia model, owing to its high toxicity in stimulating the
generation of H$_2$O$_2$ in $\beta$-cells, which may induce lipid peroxidation and the depletion of antioxidant enzymes, and even worse, organic damage$^{31-33}$. Previous publications have reported decreases in antioxidant enzyme activities, including GSH-Px, SOD and CAT, in the pancreas, liver and kidney of diabetic mice, in agreement with our present conclusions$^{34}$. Interestingly, the reductions in enzyme activities and the increase of MDA levels were markedly suppressed after treatment with HIPS1 or HIPS2 (Fig. 4), demonstrating that the polysaccharides may inhibit oxidative damage to pancreatic, hepatic and nephritic tissue. Pancreas, one of the most vital organs of polysaccharide metabolism, maintains homeostasis of blood glucose through insulin synthesis. STZ exhibits toxicity on pancreatic $\beta$-cells, leading to pancreatic damage, and results in disordered insulin secretion$^{32,33}$. As sensitive organs, the liver and kidneys have a great capacity to detoxify toxic substances, and they play pivotal roles in glucose metabolism in vivo$^{31}$. Therefore, the pathological damages that are inflicted on the liver and kidneys by hepatotoxic and nephrotoxic agents appear to be fatal in diabetes$^{35,36}$. Furthermore, in diabetic animals, the oxidative stress that is induced by free radicals can affect the functions of the pancreas, liver and kidneys$^{37}$. In the present work, as shown in Figs 5–7, the STZ-induced diabetic mice exhibited serious damage to the pancreas, liver and kidneys$^{37}$. In the present work, as shown in Figs 5–7, the STZ-induced diabetic mice exhibited serious damage to the pancreas, liver and kidneys, including cell necrosis, hypochromatosis, fatty degeneration and glomerular proliferation. Interestingly, this damage was considerably recovered by HIPS1 and HIPS2 administration, indicating that the damage to the pancreas, liver and kidneys in STZ-induced diabetic mice can be protected and repaired by intervention with HIPS1 and HIPS2.

High blood glucose levels are the main characteristic of DM$^{1}$. In STZ-induced diabetic mice, high GLU levels and increased uptake of food and water indicate the successful establishment of the model$^{38}$. One therapeutic approach for decreasing hyperglycaemia is to retard the absorption of glucose by inhibition of carbohydrate hydrolysis enzymes, such as $\alpha$-amylase and $\alpha$-glucosidase. Hence, it is important to investigate the inhibition of $\alpha$-amylase and $\alpha$-glucosidase to analyse the antihyperglycaemic effects$^{37,39}$. In the present study, HIPS1 and
HIPS2 produced inhibitory effects against the two enzymes at different concentrations, and HIPS1 was more effective than HIPS2, apparently due to the different structures of the polysaccharides. Nevertheless, Chiba noted that the inhibitory effects may be associated with the individual structures of the enzymes\(^\text{49}\). Blood has direct contact with most of the tissues in the animal body, and pathological changes are likely to be reflected in levels of some proteins and enzymes in blood samples\(^\text{50}\). Enhanced ALB levels and decreased activities of ALP, ALT and AST in serum have been used clinically as biochemical markers for liver damage\(^\text{61, 42}\). BUN and CRE, endogenous by-products that are released into body fluids and excreted by glomerular filtration, have been widely used in the clinic to reflect the physical status of the kidneys\(^\text{43}\). In the present study, changes in the activities of ALB, ALT, AST, and and in serum levels of BUN and CRE were suppressed by HIPS1 and HIPS2 administration, indicating the stabilization of plasma membranes and repair of STZ-induced pancreatic, hepatic and nephritic damages. These results are also consistent with our previous studies\(^\text{45}\).

The present findings suggest that HIPS1 and HIPS2 from H. erinaceus SG-02 are novel bioactive compounds with potential anti-diabetic and organic protection effects. Moreover, HIPS1 was much more efficient than HIPS2 in preventing the diabetes-induced organs damages, with the possible mechanism might be due to the monosaccharide composition and bond types. Figure 2 shows that HIPS1 contains Xly and a high percentage of Glc in the monosaccharide composition compared with HIPS2. Furthermore, HIPS1 contains more active radicals and functional groups, such as -NH\(_2\), -COOH and S=O, than HIPS2. These structural characteristics might contribute to the scavenging capacities of ROS. Moreover, HIPS1 and HIPS2, especially HIPS1, could indirectly relieve oxidative damage to the pancreas, liver and kidneys by improving the antioxidant enzyme activities and reducing MDA levels (Fig. 4), possibly resulting in the amelioration of tissue necrosis and inflammatory damage in these organs. Otherwise, the repair capacities of HIPS1 and HIPS2 on the organs may involve a reduction of insulin secretion or stimulation of insulin release\(^\text{44}\) and may indirectly participate in inflammatory pathways\(^\text{45}\), possibilities that require further study.

**Methods**

**Ethics statement.** All experiments were performed in accordance with the guidelines and regulations of the ethics committee of the Shandong Agricultural University and the Animals (Scientific Procedures) Act of 1986 (amended 2013).

All experimental protocols were submitted to and approved by the ethics committee of the Shandong Agricultural University in accordance with the Animals (Scientific Procedures) Act of 1986 (amended 2013).

**Materials.** The H. erinaceus SG-02 strain used in this experiment was preserved in the Fungi and Application Laboratory of Shandong Agriculture University (Taian, China) and was maintained on a potato dextrose agar (PDA) slant. The diagnostic kits for analysing SOD, GSH-Px, and CAT activities and MDA levels were purchased from the Nanjing Jiancheng Bioengineering Institute (Nanjing, China). The standard monosaccharide samples, including rhamnose (Rha), ribose (Rib), arabinose (Ara), Xyl, Glc, Man and Gal, were provided by the Merck Company (Darmstadt, Germany) and the Sigma Chemical Company (St. Louis, MO, USA). All other reagents and chemicals used in the present work were analytical reagent grade and were supplied by local chemical suppliers.

**Isolation and purification of polysaccharides.** H. erinaceus SG-02 was initially maintained on PDA slants and then inoculated into 500 mL of liquid medium containing glucose (10 g), peptone (1.5 g), yeast extract, (2 g), KH\(_2\)PO\(_4\) (1 g) and MgSO\(_4\) (0.5 g). After 25 days of fermentation, the mycelia of H. erinaceus SG-02 were collected and cleaned three times with distilled water. The dry mycelia were shattered and extracted with distilled water at 80°C for 3 h and centrifuged at 3000 rpm for 10 min, after which the precipitate was discarded. The supernatant was mixed with anhydrous ethanol (4°C overnight) to obtain the crude polysaccharide, which was deproteinized using Sevag reagent (chloroform/n-butanol, 5:1, v/v) and labelled as HIPS.

HIPS (1 g) was dissolved in 15 mL of distilled water and purified on a DEAE-cellulose column (26 × 400 mm) at a flow rate of 2.0 mL/min and eluted with sodium chloride solutions at concentrations of 0, 0.2, 0.3 and 0.5 mol/L. The major eluate was then collected separately and purified by gel permeation chromatography (Sephadex G-100 column AQ3, 1.3 × 50 cm). The above steps were repeated twenty times, and the main fractions were lyophilized by vacuum freeze-drying (Labconco, USA) for further study.

**UV spectroscopy, GC and FT-IR analysis of polysaccharides.** The UV scanning spectrum was determined by microplate spectrophotometer (Dynex Spectra MR, Dynex Technologies, USA)

The monosaccharide composition was determined by GC (GC-2010, Shimadzu, Japan) according to the method of Sheng, et al.\(^\text{46}\). The monosaccharide compositions were identified by comparing the retention times with the standards, and the monosaccharide contents were calculated using area normalization methods.

Infrared spectra of the samples were recorded using an infrared spectrometer ( Nicolet 6700, Thermo Fisher Scientific, USA) with a range of 400–4000 cm\(^{-1}\).

**Inhibition assay on α-amylase and α-glucosidase activities.** The HIPS fractions were stored at −80°C prior to the assay of α-amylase inhibition. The reaction mixture, including 0.2 mL of α-amylase (6 U/mL) and 0.2 mL of polysaccharide solution (1.0 to 6.0 mg/mL, dissolved in 0.2 mol/L phosphate buffer, pH 6.6), was activated by adding the starch substrate solution (0.4 mL, 1%, w/w) and was processed at 37°C for 10 min, followed by termination with 2 mL of DNS reagent (1% 3,5-dinitrosalicylic acid and 12% sodium potassium tartrate in 0.4 mol/L sodium hydroxide)\(^\text{48}\). The sample was maintained in boiling water for 10 min and then diluted with 15 mL of distilled water in an ice bath. The α-amylase activity was determined by measuring the absorbance at 540 nm. The IC50 value was defined as the concentration of polysaccharide that produced an inhibition rate of 50% under the assay conditions\(^\text{19}\).
where $A_i$ was the absorbance of the mixture that includes 0.2 mL of phosphate buffer, 0.2 mL of $\alpha$-amylase solution; $A_1$ was the absorbance of the mixture that includes 0.2 mL of sample, 0.2 mL of $\alpha$-amylase solution, and 0.2 mL of sample.

Inhibition of $\alpha$-glucosidase activity was measured according to reported methods with some modifications. The $\alpha$-glucosidase (0.2 mL, 3.75 U/mL) was premixed with the samples (dissolved in 0.2 mol/L phosphate buffer, pH 6.8) at various concentrations (0.5 to 6.0 mg/mL), and 6 mmol/L p-nitrophenyl-$\alpha$-D-glucopyranoside (in phosphate buffer) as a substrate was added to the mixture to initiate the reaction. The reaction was incubated at 37°C for 30 min and stopped by adding 6 mL of 0.1 mol/L sodium carbonate. The $\alpha$-glucosidase activity was determined by measuring the absorbance at 400 nm.

\[
\text{Inhibition rate} (\%) = \left(1 - \frac{(A_i - A_j)}{A_i}\right) \times 100
\]  
(1)

where $A_i$ was the absorbance of the mixture that includes 0.2 mL of phosphate buffer, 0.2 mL of p-nitrophenyl-$\alpha$-D-glucopyranoside solution, and 0.2 mL of $\alpha$-glucosidase solution; $A_1$ was the absorbance of the mixture that includes 0.2 mL of sample, 0.2 mL of p-nitrophenyl-$\alpha$-D-glucopyranoside solution, and 0.2 mL of $\alpha$-glucosidase solution; and $A_j$ was the absorbance of the mixture that includes 0.2 mL of phosphate buffer, $\alpha$-glucosidase solution, and 0.2 mL of sample.

Animal experiments. Ninety Kunming strain mice (4 weeks old, weight: 20 ± 2 g, purchased from Taibang Biological Products Ltd. Co. (Taian, China)) were acclimated for one week under the following conditions: temperature (23 ± 1°C), humidity (55 ± 5%) and a 12-h light-dark cycle, during which time they had free access to food and water ad libitum. After the acclimation, the mice were induced to become diabetic by an intraperitoneal injection with 120 mg/kg STZ (freshly dissolved in sodium citrate buffer, pH 4.5), while the NC group was injected intraperitoneally with citrate buffer. The GLU levels in the blood samples obtained from the tail of each mouse were measured 48 h after the last STZ injection using an ACCU-CHEK blood glucose metre (Roche, Basel, Switzerland). Mice with GLU levels greater than 13.3 mmol/L were considered successful models of diabetes.

The pancreas, liver and kidneys were removed rapidly, weighed, and homogenized (1:9, w/v) in phosphate-buffered solution (PBS, 0.2 mol/L, pH 7.4). After centrifugation at 4°C for 30 min (5000 rpm), the supernatants were collected and assayed for the hepatic/nephritic activities of GSH-Px, SOD, and CAT and MDA levels according to the commercial kit instructions. These results may provide a mechanistic basis for the use of $H. erinaceus$ SG-02 as potentially natural and functional foods and drugs for the prevention and alleviation of diabetes and its complications.
References

1. Kuzuya, T. et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res. Clin. Pr. 55, 65–85 (2002).
2. AlMatar, M., Islam, M. R., Albari, O., Var, I., & Köksal, F. Pomegranate as a possible treatment in reducing risk of developing wound healing, obesity, neurodegenerative disorders, and diabetes mellitus. Mini-Rev. Med. Chem. 18 (2017).
3. Hong, S. Y. et al. Hepatitis B and C virus infection and diabetes mellitus: A cohort study. Sci. Rep. 2017, doi:10.1038/s41598-017-04206-6 (2017).
4. Krischer, J. P. et al. Genetic and environmental interactions modify the risk of diabetes-related autoimmunity by 6 years of age: the teddy study. Diabetes care. 2017, doi:10.2337/dc17-0238 (2017).
5. Bao, W. et al. Prepregnancy low-carbohydrate diet scores and the risk of gestational diabetes mellitus: a prospective cohort study. Am. J. Clin. Nutr. 99, 1378 (2013).
6. Jontczk-Skórka, K. & Kowalski, J. The assessment of risk factors for glucose metabolism disorders. Pol. Merkur. Lekarski. 42, 241–246 (2017).
7. Baynes, J. W. Role of oxidative stress in development of complications in diabetes. Diabetes. 40, 405–412 (1991).
8. Fridlyand, L. E. & Philipson, L. H. Oxidative reactive species in cell injury: Mechanisms in diabetes mellitus and therapeutic approaches. JAMA. 1066, 136–151 (2005).
9. Siman, C. M. & Eriksson, U. J. Vitamin e decreases the occurrence of malformations in the offspring of diabetic rats. Diabetes 46, 1054–1061 (1997).
10. Ohkusu, T., Sato, Y. & Naoi, M. Hydroxyl radical formation in diabetic rats induced by streptozotocin. Life Sci. 56, 1789–1798 (1995).
11. Rakieten, N., Rakieten, M. L. & Nadkarni, M. R. Studies on the diabetogenic action of streptozotocin (nsc-37917). Cancer Chemother Rep. 29, 91–98 (1963).
12. Moussa, S. A. Oxidative stress in diabetes mellitus. Rom. J. Bioph. 18, 225–236 (2008).
13. Lee, B. R. et al. Amelioration of streptozotocin-induced diabetes by agrocybe chaxingu polysaccharide. Mol. Cells. 29, 349–354 (2010).
14. Lakey, J. R. et al. Peroxynitrite is a mediator of cytokine-induced destruction of human pancreatic islet beta cells. Lab. Invest. 81, 1683–1692 (2001).
15. Naso, F. C. D., Dias, A. S., Porawski, M. & Marroni, N. A. Exogenous superoxide dismutase: action on liver oxidative stress in animals with streptozotocin-induced diabetes. Exp. Diabetes Res. 2011, 754132. doi:10.1155/2011/754132 (2011).
16. Eum, W. S. et al. HIV-1 mediated protein transduction of Cu, Zn-superoxide dismutase into pancreatic beta cells in vitro and in vivo. Free Radic. Biol. Med. 37, 339–349 (2004).
17. Grover, J. K., Yadav, S. & Vats, V. Medicinal plants of India with anti-diabetic potential. J. Ethnopharmacol. 81, 81–100 (2002).
18. Lebovitz, H. E. Effect of the postprandial state on nontraditional risk factors. Am. J. Cardiol. 88, 20H–5 (2001).
19. Ukil, A., Wang, M. H. & Rhee, H. I. A novel a-glucosidase inhibitor from pine bark. Carbohydr. Res. 339, 715–717 (2004).
20. Friedman, M. Mushroom Polysaccharides: Chemistry and Antiobesity, Antidiabetes, Anticancer, and Antibiotic Properties in Cells, Rodents, and Humans. Foods. 5, 80 (2016).
21. Kim, S. W. et al. Effect of fungal polysaccharides on the modulation of plasma proteins in streptozotocin-induced diabetic rats. Polym. Sci. 6, 5291–5302 (2006).
22. Wang, M., Gao, Y., Xu, D., Komishi, T. & Gao, Q. Hericium erinaceus (yamabushitake): a unique resource for developing functional foods and medicines. Food Funct. 5, 3055–3064 (2014).
23. He, X. R. et al. Structures, biological activities, and industrial applications of the polysaccharides from Hericium erinaceus (Lion’s Mane mushroom): A Review. Int. J. Biol. Macromol. 97, 228–237 (2017).
24. Liu, M. H. & Wu, H. Y. The research progress of anti-oxidation effect of traditional Chinese medicine polysaccharide. J. Tradit. Chin. Med. 28, 326–327 (2012).
25. Mukhiddinov, Z. K., Khalikov, D. K., Abdusamiev, F. T. & Avloev, C. C. Isolation and structural characterization of a pectin homo polysaccharide from Lycium barbarum and ramnogalacturonan. Int. J. Biol. Macromol. 60, 235–240 (2013).
26. Maritinn, A. C., Sanders, R. A. & Watkins, J. B. Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 17, 24–38 (2003).
27. Qiu, T., Ma, X., Ye, M., Yuan, R. & Wu, Y. Purification, structure, lipid lowering and liver protecting effects of polysaccharide from Lachnum yam281. Carbohydr. Polym. 98, 922–930 (2013).
28. Moussa, S. A. Oxidative stress in diabetes mellitus. Rom. J. Bioph. 18, 225–236 (2008).
29. Coskun, O., Kanter, M., Korkmaz, A. & Oter, S. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and β-cell damage in rat pancreas. Pharmcol. Res. 51, 117–123 (2004).
30. Friesen, N. T. E., Bückh, A. S., Schott-Olth, P., Lgsstar, A. & Gleichmann, H. Generation of hydrogen peroxide and failure of antioxidative responses in pancreatic islets of male c57bl/6 mice are associated with diabetes induced by multiple low doses of streptozotocin. Diabetologia. 47, 676–685 (2004).
31. Srivivasan, A., Menon, V. P., Periaswamy, V. & Rajasekaran, K. N. Protection of pancreatic beta-cell by the potential antioxidant bis-o-hydroxycinnamoyl methane, analogue of natural curcuminoid in experimental diabetes. J. Pharm. Sci. 6, 327–333 (2000).
32. Andallu, B. & Nich, V. Antioxidant role of mulberry (Morus indica. L. cv. Amnatha) leaves in streptozotocin-diabetic rats. Clin. Chim. Acta. 338, 3–10 (2004).
33. Devi, B. A., Kamalakannan, N. & Prince, P. S. Supplementation of fenugreek leaves to diabetic rats. effect on carbohydrate metabolic enzymes in diabetic liver and kidney. Phytother. Res. 17, 1231–1233 (2003).
34. Dinis-Oliveira, R. J. et al. Single high dose dexamethasone treatment decreases the pathological score and increases the survival rate of paraquat-intoxicated rats. Toxicology. 227, 73–85 (2006).
35. Li, X. M. Protective effect of Lycium barbarum polysaccharides on streptozotocin-induced oxidative stress in rats. Int. J. Biol. Macromol. 40, 461–465 (2007).
36. Goyal, B. R., Parmar, K., Goyal, R. K. & Mehta, A. A. Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats. Pharmcol. Rep. 63, 956–966 (2011).
37. Toedler, M. Alpha-glucosidase inhibitors in diabetes: efficacy in NIDDM subjects. Eur. J. Clin. Invest. 24, 31–35 (1994).
38. Chiba, S. Molecular mechanism in alpha-glucosidase and glucoamylase. Biosci. Biotechnol. Biochem. 61, 1233–1239 (1997).
39. Jiang, C. X. et al. Antioxidant activity and potential hepatoprotective effect of polysaccharides from Cyclina sinus. Carbohydr. Polym. 91, 262–268 (2013).
40. Kasdallah-Grissa, A. et al. Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver. Life Sci. 80, 1033–1039 (2007).
41. Stevens, L. A. & Levy, A. S. Chronic kidney disease in the elderly-how to assess risk. N. Engl. J. Med. 352, 2122–2124 (2005).
42. Das, A. V., Padayatti, P. S. & Paulose, C. S. Effect of leaf extract of Aegle marmelos (L.) Correa ex Roxb. On histological and ultrastructural changes in tissues of streptozotocin induced diabetic rats. Indian J. Exp. Biol. 34, 341–345 (1996).
45. Ji, X. Q. et al. Andrographolide ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated renal oxidative stress and inflammation via Akt/NF-κB pathway. Mol. Cell. Endocrinol. 437, 268–279 (2016).
46. Sheng, J. C. et al. H. Preparation, identification and their antitumor activities in vitro of polysaccharides from Chlorella pyrenoidosa. Food Chem. 105, 533–539 (2007).
47. Zheng, L. et al. Antihyperlipidemic and hepatoprotective activities of mycelia zinc Polysaccharide from Pholiota nameko SW-02. Int. J. Biol. Macromol. 70, 523–529 (2014).
48. Maeda, K., Kakabayashi, S. & Matsubara, H. Complete amino acid sequence of an alpha-amylase inhibitor in wheat kernel (0.19-inhibitor). Biochim. Biophys. Acta. 828, 52–57 (1985).
49. Liu, Y., Sun, J., Rao, S., Su, Y. & Yang, Y. Antihyperglycemic, antihyperlipidemic and antioxidant activities of polysaccharides from Catathelasma ventricosum in streptozotocin-induced diabetic mice. Food Chem. Toxicol. 57, 39–45 (2013).
50. Aksoy, N., Vural, H., Sabuncu, T. & Aksoy, S. Effects of melatonin on oxidative-antioxidative status of tissues in streptozotocin-induced diabetic rats. Cell Biochem. Funct. 21, 121–125 (2003).
51. Lin, L. et al. Antioxidative and renoprotective effects of residue polysaccharides from Flammulina velutipes. Carbohydr. Polym. 146, 388–395 (2016).
52. Chao, J. et al. Analgesic and anti-inflammatory activities of ethanol root extract of Mahonia oiwakensis in mice. J. Ethnopharmacol. 125, 297–303 (2009).

Acknowledgements
This work was supported by grants from Mushroom Technology System of Shandong Province (SDAIT-07-05) and Fundamental Research Funds for Central Non-profit Scientific Institution (1610132016041).

Author Contributions
Chen Zhang and Le Jia designed the research. Chen Zhang, Chunlong Hu and Jianjun Zhang analyzed data. Chen Zhang and Jianjun Zhang performed research. Chen Zhang, Chunlong Hu, Zhenzhen Ren and Xinling Song prepared figures and table. Chen Zhang wrote the manuscript. Juan Li and Jing Wang contributed to the improvements of the English language. All authors were involved in checked the paper and contributed to the preparation of the final manuscript. All authors read and approved the final manuscript.

Additional Information
Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017